GTX INC Contracts & Agreements
232 Contracts & Agreements
- Business Finance (49 contracts)
- Business Operations (40)
- Human Resources (74)
- Intellectual Property (24)
- Mergers & Acquisitions (2)
- Real Estate (8)
- Uncategorized (35)
- Amended and Restated License Agreement between Oncternal Oncology, Inc. and The Regents of the University of California dated August 6, 2024 (Filed With SEC on August 8, 2024)
- Non-Employee Director Compensation Program (Filed With SEC on May 9, 2024)
- Description of Securities of the Registrant (Filed With SEC on March 7, 2024)
- Non-Employee Director Compensation Program of Registrant (Filed With SEC on March 7, 2024)
- 2015 Equity Incentive Plan of Private Oncternal, as amended (the 2015 Plan) (Filed With SEC on March 7, 2024)
- 2019 Incentive Award Plan of the Registrant (the 2019 Plan) (Filed With SEC on March 7, 2024)
- 2021 Employment Inducement Incentive Award Plan of the Registrant, as amended (the Inducement Plan) (Filed With SEC on March 7, 2024)
- Second Amendment to the UTRF License Agreement dated March 4, 2024 (Filed With SEC on March 7, 2024)
- Amendment #4 to the Amended and Restated License Agreement between Oncternal Therapeutics, Inc. and UC San Diego dated August 31, 2018 (Filed With SEC on January 23, 2024)
- Advisory Services Agreement effective June 14, 2023 between the Registrant and Gunnar F. Kaufmann, Ph.D (Filed With SEC on August 10, 2023)
- First Amendment to the Amended and Restated License Agreement Between the University of Tennessee Research Foundation and the Registrant dated August 22, 2022 (Filed With SEC on November 3, 2022)
- Description of Securities of the Registrant (Filed With SEC on March 10, 2022)
- Amended and Restated License Agreement between the University of Tennessee Research Foundation and the Registrant Oncternal Therapeutics, Inc. dated March 9, 2022 (Filed With SEC on March 10, 2022)
- 2019 Incentive Award Plan of the Registrant effective June 7, 2019 (the 2019 Plan) (Filed With SEC on March 10, 2022)
- Form of Stock Option Agreement under the 2019 Plan (Filed With SEC on March 10, 2022)
- Form of Restricted Stock Unit under the 2019 Plan (Filed With SEC on March 10, 2022)
- Form of Stock Option under the Inducement Plan (Filed With SEC on March 10, 2022)
- Amendment No. 2 to the Inducement Plan dated December 15, 2021 (Filed With SEC on March 10, 2022)
- Open Market Sale Agreement (Filed With SEC on December 17, 2021)
- First Amendment to Contingent Value Rights Agreement dated November 1, 2021 by and between the Registrant, Marc S. Hanover, as the Holders Representative, and Computershare Inc.,... (Filed With SEC on November 4, 2021)
- Amended and Restated Employment Agreement dated January 6, 2021 between Oncternal Therapeutics, Inc. and Raj Krishnan, Ph.D (Filed With SEC on August 5, 2021)
- Employment Agreement dated April 12, 2021 between Oncternal Therapeutics, Inc. and Chase Leavitt (Filed With SEC on August 5, 2021)
- Employment Agreement dated May 17, 2021 between Oncternal Therapeutics, Inc. and Salim Yazji, M.D (Filed With SEC on August 5, 2021)
- Open Market Sale Agreement (Filed With SEC on May 28, 2021)
- Amendment No. 1 to the Oncternal Therapeutics, Inc. 2021 Employment Inducement Incentive Award Plan (Filed With SEC on May 28, 2021)
- Office Lease between Cognac Del Mar Owner II LLC and Registrant dated March 17, 2021 (Filed With SEC on May 6, 2021)
- Non-Employee Director Compensation Policy, as amended and restated, effective March 18, 2021 (Filed With SEC on May 6, 2021)
- Employment Transition Agreement between Frank Hsu, M.D. and Registrant, dated February 24, 2021 (Filed With SEC on May 6, 2021)
- Amendment #3 to Amended and Restated License Agreement between Oncternal Therapeutics, Inc. and the Regents of the University of California, dated February 5, 2021 (Filed With SEC on March 11, 2021)
- Engagement Letter between the Registrant and H.C. Wainwright & Co., LLC, dated as of December 9, 2020 (Filed With SEC on March 11, 2021)
- Oncternal Therapeutics, Inc. 2021 Employment Inducement Incentive Award Plan and form of stock option agreement thereunder (Filed With SEC on February 17, 2021)
- Amended and Restated Underwriting Agreement, dated December 9, 2020, by and between Oncternal Therapeutics, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on December 11, 2020)
- Form of Underwriter Warrant (Filed With SEC on December 11, 2020)
- Amended and Restated Underwriting Agreement, dated November 17, 2020, by and between Oncternal Therapeutics, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on November 19, 2020)
- Form of Underwriter Warrant (Filed With SEC on November 19, 2020)
- Amended and Restated Underwriting Agreement, dated August 27, 2020, by and between Oncternal Therapeutics, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on August 31, 2020)
- Form of Underwriter Warrant (Filed With SEC on August 31, 2020)
- Amendment #4 to Collaboration Agreement between Oncternal Therapeutics, Inc. and The University of Texas M.D. Anderson Cancer Center, dated February 19, 2020 (Filed With SEC on August 6, 2020)
- Form of Warrant (Filed With SEC on July 21, 2020)
- Form of Placement Agent Warrant (Filed With SEC on July 21, 2020)
- Form of Securities Purchase Agreement (Filed With SEC on July 21, 2020)
- Form of Warrant (Filed With SEC on May 21, 2020)
- Form of Placement Agent Warrant (Filed With SEC on May 21, 2020)
- Form of Securities Purchase Agreement (Filed With SEC on May 21, 2020)
- Engagement Letter between Oncternal Therapeutics, Inc. and H.C. Wainwright & Co., LLC, dated as of May 15, 2020 (Filed With SEC on May 21, 2020)
- Description of Securities of Oncternal Therapeutics, Inc (Filed With SEC on March 16, 2020)
- Amendment No. 1 to Commercial License Agreement between Selexis SA and Oncternal Therapeutics, Inc., dated February 7, 2020 (Filed With SEC on March 16, 2020)
- Amendment #2 to Amended and Restated License Agreement between Oncternal Therapeutics, Inc. and the Regents of the University of California, dated May 15, 2019 (Filed With SEC on March 16, 2020)
- Form of Indemnification Agreement (Filed With SEC on March 16, 2020)
- Consulting Agreement dated September 20, 2019 between Robert J. Wills. Ph.D. and Oncternal Therapeutics, Inc (Filed With SEC on March 16, 2020)
- Employment Agreement dated August 26, 2019 between Oncternal Therapeutics, Inc. and Frank Hsu, M.D (Filed With SEC on November 8, 2019)
- Employment Agreement dated September 5, 2019 between Oncternal Therapeutics, Inc. and Gunnar F. Kaufmann, Ph.D (Filed With SEC on November 8, 2019)
- Employment Agreement dated September 9, 2019 between Oncternal Therapeutics, Inc. and Igor P. Bilinsky, Ph.D (Filed With SEC on November 8, 2019)
- Employment Agreement dated September 12, 2019 between Oncternal Therapeutics, Inc. and James B. Breitmeyer, M.D (Filed With SEC on November 8, 2019)
- Employment Agreement dated September 5, 2019 between Oncternal Therapeutics, Inc. and Richard G. Vincent (Filed With SEC on November 8, 2019)
- Employment Agreement dated September 5, 2019 between Oncternal Therapeutics, Inc. and Hazel M. Aker (Filed With SEC on November 8, 2019)
- Amended Oncternal Therapeutics, Inc. Annual Incentive Plan (Filed With SEC on November 8, 2019)
- Specimen of Common Stock Certificate (Filed With SEC on August 9, 2019)
- Sublease by and between Oncternal Therapeutics, Inc. and Host Hotels & Resorts, L.P., dated May 22, 2019 (Filed With SEC on August 9, 2019)
- Form of Amendment to Warrant to Purchase shares of Series B-2 Preferred Stock of Oncternal Therapeutics, Inc (Filed With SEC on August 9, 2019)
- CVR Agreement, dated as of June 7, 2019, by and between the Registrant, Marc S. Hanover, as the Holders Representative, and Computershare Investor Services, as Rights Agent (Filed With SEC on June 10, 2019)
- Amendment No. 1 to Agreement and Plan of Merger and Reorganization, dated April 30, 2019, by and among GTx, Oncternal and Merger Sub (Filed With SEC on April 30, 2019)
- Form of CVR Agreement by and between GTx, Marc S. Hanover, as the Holders Representative, and Computershare Investor Services, as Rights Agent (Filed With SEC on April 30, 2019)
- Form of Warrant to purchase shares Series B-2 Preferred Stock of Oncternal Therapeutics, Inc (Filed With SEC on April 8, 2019)
- Commercial License Agreement between Selexis SA (predecessor to Oncternal Therapeutics, Inc.) and ROAR Therapeutics, LLC, dated May 19, 2014 (Filed With SEC on April 8, 2019)
- Exclusive License Agreement between Georgetown University and Oncternal Therapeutics, Inc., dated March 26, 2014 (Filed With SEC on April 8, 2019)
- Amendment to Exclusive License Agreement between Georgetown University and Oncternal Therapeutics, Inc., dated March 17, 2016 (Filed With SEC on April 8, 2019)
- Collaboration Agreement between Oncternal Therapeutics, Inc. and The University of Texas M.D. Anderson Cancer Center, dated December 15, 2014 (Filed With SEC on April 8, 2019)
- Amendment #1 to Collaboration Agreement between Oncternal Therapeutics, Inc. and The University of Texas M.D. Anderson Cancer Center, dated January 24, 2016 (Filed With SEC on April 8, 2019)
- Amendment #2 to Collaboration Agreement between Oncternal Therapeutics, Inc. and The University of Texas M.D. Anderson Cancer Center, dated May 1, 2016 (Filed With SEC on April 8, 2019)
- Amendment #3 to Collaboration Agreement between Oncternal Therapeutics, Inc. and The University of Texas M.D. Anderson Cancer Center, dated September 17, 2018 (Filed With SEC on April 8, 2019)
- Research agreement between Oncternal Therapeutics, Inc. and the Regents of the University of California, on behalf of its San Diego Campus, dated November 3, 2016 (Filed With SEC on April 8, 2019)
- License Agreement between Oncternal Therapeutics, Inc. and Velos Biopharma Holdings, LLC, dated February 6, 2018 (Filed With SEC on April 8, 2019)
- Amended and Restated License Agreement between Oncternal Therapeutics, Inc. and The Regents of the University of California, dated August 31, 2018 (Filed With SEC on April 8, 2019)
- Amendment #1 to Amended and Restated License Agreement between Oncternal Therapeutics, Inc. and the Regents of the University of California, dated March 25, 2019 (Filed With SEC on April 8, 2019)
- Oncternal Therapeutics, Inc. 2015 Equity Incentive Plan, as amended (Filed With SEC on April 8, 2019)
- Form of Stock Option Agreement under the Oncternal Therapeutics, Inc. 2015 Equity Incentive Plan, as amended (Filed With SEC on April 8, 2019)
- Form of Early Exercise Stock Option Agreement under the Oncternal Therapeutics, Inc. 2015 Equity Incentive Plan, as amended (Filed With SEC on April 8, 2019)
- Restricted Stock Purchase Agreement dated May 22, 2017, between Oncternal Therapeutics, Inc. and Richard G. Vincent (Filed With SEC on April 8, 2019)
- Restricted Stock Purchase Agreement dated December 14, 2017, between Oncternal Therapeutics, Inc. and Richard G. Vincent (Filed With SEC on April 8, 2019)
- Restricted Stock Purchase Agreement dated December 14, 2017, between Oncternal Therapeutics, Inc. and William R. LaRue (Filed With SEC on April 8, 2019)
- Restricted Stock Purchase Agreement dated May 9, 2018, between Oncternal Therapeutics, Inc. and Charles Theuer, M.D., Ph.D (Filed With SEC on April 8, 2019)
- Employment Letter dated May 31, 2017, between Oncternal Therapeutics, Inc. and James B. Breitmeyer, M.D., Ph.D (Filed With SEC on April 8, 2019)
- Employment Letter dated January 1, 2019, between Oncternal Therapeutics, Inc. and Richard G. Vincent (Filed With SEC on April 8, 2019)
- Consulting Agreement dated April 3, 2017, between Oncternal Therapeutics, Inc. and Richard G. Vincent (Filed With SEC on April 8, 2019)
- License Agreement, effective March 1, 2015, between the Registrant and University of Tennessee Research Foundation (Filed With SEC on March 18, 2019)
- Amendment #1 to the License Agreement, dated November 12, 2015, between the Registrant and University of Tennessee Research Foundation (Filed With SEC on March 18, 2019)
- Amendment #2 to the License Agreement, as amended, dated August 12, 2016, between the Registrant and University of Tennessee Research Foundation (Filed With SEC on March 18, 2019)
- Amendment #3 to the License Agreement, as amended, dated April 6, 2017, between the Registrant and University of Tennessee Research Foundation (Filed With SEC on March 18, 2019)
- Amendment #4 to the License Agreement, as amended, dated October 23, 2018, between the Registrant and University of Tennessee Research Foundation (Filed With SEC on March 18, 2019)
- Form of CVR Agreement by and between GTx, Marc S. Hanover, as the Holders Representative, and Computershare Investor Services, as Rights Agent (Filed With SEC on March 7, 2019)
- Form of GTx Voting Agreement, dated March 6, 2019, by and between Oncternal, GTx and each of the parties named in each agreement therein (Filed With SEC on March 7, 2019)
- Form of Oncternal Voting Agreement, dated March 6, 2019, by and between GTx, Oncternal and each of the parties named in each agreement therein (Filed With SEC on March 7, 2019)
- Form of Lock-Up Agreement, dated March 6, 2019, by each of the parties named in each agreement therein (Filed With SEC on March 7, 2019)
- Agreement and Plan of Merger and Reorganization, dated March 6, 2019, by and among GTx, Oncternal and Merger Sub (Filed With SEC on March 7, 2019)
- 2018 Compensation Information for Registrants Executive Officers (Filed With SEC on May 15, 2018)
- First Amendment to Office Lease, dated March 8, 2018, between Registrant and Hertz Memphis Three LLC (Filed With SEC on May 15, 2018)
- At-the-Market Equity Offering Sales Agreement by and between GTx, Inc. and Stifel, Nicolaus & Company, Incorporated, dated February 9, 2018 (Filed With SEC on February 9, 2018)
- Purchase Agreement, dated September 25, 2017, between GTx, Inc. and the purchasers identified in Exhibit A therein (including the Form of Warrant attached thereto as Exhibit B) (Filed With SEC on September 29, 2017)
- LOAN AGREEMENT (Filed With SEC on August 14, 2017)
- 2017 Compensation Information for Registrants Executive Officers (Filed With SEC on May 15, 2017)
- GENOTHERAPEUTICS, INC. STOCK OPTION PLAN (Filed With SEC on March 24, 2017)
- GTX, INC. 2000 STOCK OPTION PLAN (Filed With SEC on March 24, 2017)
- GTX, INC. 2001 STOCK OPTION PLAN (Filed With SEC on March 24, 2017)
- GTx, Inc. 2002 STOCK OPTION PLAN (Filed With SEC on March 24, 2017)
- GTX, INC. 2004 EQUITY INCENTIVE PLAN Adopted January 14, 2004 Approved By Stockholders January 14, 2004 Amended by the Board March 6, 2008 Approved by Stockholders April 30, 2008... (Filed With SEC on March 24, 2017)
- GTX, INC. AMENDED AND RESTATED 2004 NON-EMPLOYEE DIRECTORS STOCK OPTION PLAN Adopted January 14, 2004 Approved by Stockholders January 14, 2004 Amended and Restated on February... (Filed With SEC on March 24, 2017)
- GTX, INC. 2013 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD: FEBRUARY 14, 2013 APPROVED BY THE STOCKHOLDERS: MAY 2, 2013 AMENDED AND RESTATED BY THE BOARD: FEBRUARY 12, 2015... (Filed With SEC on March 24, 2017)
- GTX, INC. 2013 NON-EMPLOYEE DIRECTOR EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD: FEBRUARY 14, 2013 APPROVED BY THE STOCKHOLDERS: MAY 2, 2013 (Filed With SEC on March 24, 2017)
- EMPLOYMENT AGREEMENT (Filed With SEC on March 24, 2017)
- GTX, INC. DIRECTORS DEFERRED COMPENSATION PLAN (AMENDED AND RESTATED EFFECTIVE FEBRUARY 18, 2016) ARTICLE 1 DEFINITIONS (Filed With SEC on March 24, 2017)
- SUBSCRIPTION AGREEMENT (Filed With SEC on October 12, 2016)
- GTX, INC. WARRANT AMENDMENT AGREEMENT (Filed With SEC on May 10, 2016)
- 2016 Compensation Information for Registrants Executive Officers (Filed With SEC on May 10, 2016)
- 2015 Compensation Information for Registrants Executive Officers (Filed With SEC on March 15, 2016)
- GTX, INC. DIRECTORS DEFERRED COMPENSATION PLAN (AMENDED AND RESTATED EFFECTIVE FEBRUARY 18, 2016) (Filed With SEC on March 15, 2016)
- Non-Employee Director Compensation Policy of GTx, Inc. Effective Date: January 1, 2016 (Filed With SEC on March 15, 2016)
- EMPLOYMENT AGREEMENT (Filed With SEC on November 9, 2015)
- OFFICE LEASE HERTZ MEMPHIS THREE, LLC (Landlord) GTX, INC. (Tenant) TOYOTA CENTER BUILDING SUITE 700 (Filed With SEC on August 10, 2015)
- EMPLOYMENT AGREEMENT (Filed With SEC on May 11, 2015)
- GTX, INC. RESTRICTED STOCK UNIT GRANT NOTICE (2013 EQUITY INCENTIVE PLAN) (Filed With SEC on May 11, 2015)
- EXHIBIT B FORM OF WARRANT (Filed With SEC on March 16, 2015)
- AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on March 16, 2015)
- EMPLOYMENT AGREEMENT (Filed With SEC on March 16, 2015)
- 2014 Compensation Information for Registrants Executive Officers (Filed With SEC on March 16, 2015)
- 2015 Compensation Information for Registrants Executive Officers (Filed With SEC on March 16, 2015)
- Non-Employee Director Compensation Policy of GTx, Inc. Effective Date: February 12, 2015 (Filed With SEC on March 16, 2015)
- SECURITIES PURCHASE AGREEMENT (Filed With SEC on November 10, 2014)
- AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (Filed With SEC on August 5, 2014)
- GTX, INC. CONSENT, WAIVER AND AMENDMENT AGREEMENT (Filed With SEC on August 5, 2014)
- CONSULTING AGREEMENT (Filed With SEC on August 5, 2014)
- 2014 Compensation Information for Registrants Executive Officers (Filed With SEC on May 12, 2014)
- 2014 AMENDMENT TO THE AMENDED AND RESTATED EMPLOYMENT AGREEMENT BETWEEN GTx, INC. AND MARC S. HANOVER (Filed With SEC on May 12, 2014)
- GTx, INC. WAIVER AND AMENDMENT AGREEMENT (Filed With SEC on March 12, 2014)
- REGISTRATION RIGHTS AGREEMENT (Filed With SEC on March 12, 2014)
- GTx, INC. FORM OF COMMON STOCK WARRANT (Filed With SEC on March 12, 2014)
- CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE (Filed With SEC on March 12, 2014)
- 2014 Compensation Information for Registrants Executive Officers (Filed With SEC on March 12, 2014)
- SECURITIES PURCHASE AGREEMENT (Filed With SEC on March 12, 2014)
- SECURITIES PURCHASE AGREEMENT (Filed With SEC on March 4, 2014)
- GTx, INC. 175 TOYOTA PLAZA, 7THFLOOR MEMPHIS, TN 38103 (Filed With SEC on November 12, 2013)
- GTx, INC. 175 TOYOTA PLAZA, 7THFLOOR MEMPHIS, TN 38103 (Filed With SEC on November 12, 2013)
- GTx, INC. STOCK OPTION GRANT NOTICE (2013 EQUITY INCENTIVE PLAN) (Filed With SEC on November 12, 2013)
- GTx, INC. RESTRICTED STOCK UNIT GRANT NOTICE (2013 EQUITY INCENTIVE PLAN) (Filed With SEC on November 12, 2013)
- Third Memorandum of Understanding Concerning the Lease Agreement between The University of Tennessee Research Foundation and GTx, Inc. As Amended July 20, 2009 RECITALS (Filed With SEC on November 12, 2013)
- GTx, INC. STOCK OPTION GRANT NOTICE (2013 EQUITY INCENTIVE PLAN) (Filed With SEC on July 22, 2013)
- GTx, INC. STOCK OPTION GRANT NOTICE (2013 NON-EMPLOYEE DIRECTOR EQUITY INCENTIVE PLAN) (Filed With SEC on July 22, 2013)
- Second Memorandum of Understanding Concerning the Lease Agreement between The University of Tennessee Research Foundation and GTx, Inc. As Amended July 20, 2009 RECITALS (Filed With SEC on July 22, 2013)
- AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on March 5, 2013)
- AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on March 5, 2013)
- AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on March 5, 2013)
- AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on March 5, 2013)
- AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on March 5, 2013)
- 2013 Compensation Information for Registrants Executive Officers (Filed With SEC on March 5, 2013)
- GTX, INC. DIRECTORS DEFERRED COMPENSATION PLAN (AMENDED AND RESTATED EFFECTIVE FEBRUARY 14, 2013) (Filed With SEC on March 5, 2013)
- Non-Employee Director Compensation Policy of GTx, Inc. Effective Date: 2/14/2013 (Filed With SEC on March 5, 2013)
- ASSET PURCHASE AGREEMENT between: STRAKAN INTERNATIONAL S.À R.L. a company organized under the laws of Luxembourg; and GTX, INC., a Delaware corporation Dated as ofSeptember 28,... (Filed With SEC on October 3, 2012)
- 2012 Compensation Information for Registrants Executive Officers (Filed With SEC on March 2, 2012)
- CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE (Filed With SEC on March 2, 2012)
- EX-101 INSTANCE DOCUMENT (Filed With SEC on August 9, 2011)
- GTx, Inc. (Filed With SEC on June 23, 2011)
- FINANCIAL STATEMENTS (Filed With SEC on May 9, 2011)
- FINANCIAL STATEMENTS (Filed With SEC on May 9, 2011)
- FINANCIAL STATEMENTS (Filed With SEC on May 9, 2011)
- the anticipated progress of our research, development and clinical programs, including whether any future clinical trials we conduct will achieve similar results to clinical... (Filed With SEC on March 8, 2011)
- Exhibit No (Filed With SEC on October 27, 2010)
- FINANCIAL STATEMENTS (Filed With SEC on May 4, 2010)
- the anticipated progress of our research, development and clinical programs, including whether current and future clinical trials will achieve similar results to clinical trials... (Filed With SEC on March 15, 2010)
- the anticipated progress of our research, development and clinical programs, including whether current and future clinical trials will achieve similar results to clinical trials... (Filed With SEC on March 15, 2010)
- the anticipated progress of our research, development and clinical programs, including whether current and future clinical trials will achieve similar results to clinical trials... (Filed With SEC on March 15, 2010)
- the anticipated progress of our research, development and clinical programs, including whether current and future clinical trials will achieve similar results to clinical trials... (Filed With SEC on March 15, 2010)
- the anticipated progress of our research, development and clinical programs, including whether current and future clinical trials will achieve similar results to clinical trials... (Filed With SEC on March 15, 2010)
- the anticipated progress of our research, development and clinical programs, including whether current and future clinical trials will achieve similar results to clinical trials... (Filed With SEC on March 15, 2010)
- the anticipated progress of our and our collaborators research, development and clinical programs, including the timing of regulatory submissions and whether future clinical... (Filed With SEC on March 3, 2009)
- the anticipated progress of our and our collaborators research, development and clinical programs, including the timing of regulatory submissions and whether future clinical... (Filed With SEC on March 3, 2009)
- the anticipated progress of our and our collaborators research, development and clinical programs, including the timing of regulatory submissions and whether future clinical... (Filed With SEC on March 3, 2009)
- the anticipated progress of our and our collaborators research, development and clinical programs, including the timing of regulatory submissions and whether future clinical... (Filed With SEC on March 3, 2009)
- the anticipated progress of our and our collaborators research, development and clinical programs, including the timing of regulatory submissions and whether future clinical... (Filed With SEC on March 3, 2009)
- the anticipated progress of our and our collaborators research, development and clinical programs, including the timing of regulatory submissions and whether future clinical... (Filed With SEC on March 3, 2009)
- the anticipated progress of our and our collaborators research, development and clinical programs, including the timing of regulatory submissions and whether future clinical... (Filed With SEC on March 3, 2009)
- the anticipated progress of our and our collaborators research, development and clinical programs, including the timing of regulatory submissions and whether future clinical... (Filed With SEC on March 3, 2009)
- the anticipated progress of our and our collaborators research, development and clinical programs, including the timing of regulatory submissions and whether future clinical... (Filed With SEC on March 3, 2009)
- the anticipated progress of our and our collaborators research, development and clinical programs, including the timing of regulatory submissions and whether future clinical... (Filed With SEC on March 3, 2009)
- the anticipated progress of our and our collaborators research, development and clinical programs, including the timing of regulatory submissions and whether future clinical... (Filed With SEC on March 3, 2009)
- the anticipated progress of our and our collaborators research, development and clinical programs, including the timing of regulatory submissions and whether future clinical... (Filed With SEC on March 3, 2009)
- the anticipated progress of our and our collaborators research, development and clinical programs, including the timing of regulatory submissions and whether future clinical... (Filed With SEC on March 3, 2009)
- the anticipated progress of our and our collaborators research, development and clinical programs, including the timing of regulatory submissions and whether future clinical... (Filed With SEC on March 3, 2009)
- the anticipated progress of our and our collaborators research, development and clinical programs, including the timing of regulatory submissions and whether future clinical... (Filed With SEC on March 3, 2009)
- the anticipated progress of our and our collaborators research, development and clinical programs, including the timing of regulatory submissions and whether future clinical... (Filed With SEC on March 3, 2009)
- the anticipated progress of our and our collaborators research, development and clinical programs, including the timing of regulatory submissions and whether future clinical... (Filed With SEC on March 3, 2009)
- the anticipated progress of our and our collaborators research, development and clinical programs, including the timing of regulatory submissions and whether future clinical... (Filed With SEC on March 3, 2009)
- the anticipated progress of our and our collaborators research, development and clinical programs, including the timing of regulatory submissions and whether future clinical... (Filed With SEC on March 3, 2009)
- the anticipated progress of our and our collaborators research, development and clinical programs, including the timing of regulatory submissions and whether future clinical... (Filed With SEC on March 3, 2009)
- GTx, Inc. (Filed With SEC on May 6, 2008)
- Ex-10.43 Exclusive License and Collaboration Agreement (Filed With SEC on March 11, 2008)
- Ex-10.44 2008 Compensation Information for Registrant's Executive Officers (Filed With SEC on March 11, 2008)
- EX-10.45 Non-Employee Director Compensation Arrangements (Filed With SEC on March 11, 2008)
- EX-10.46 Sublease Agreement (Filed With SEC on March 11, 2008)
- Exhibit No (Filed With SEC on December 18, 2007)
- EX-10.7 Directors' Deferred Compensation Plan (Filed With SEC on November 9, 2007)
- EX-10.40 Consolidated, Amended, License Agreement (Filed With SEC on November 9, 2007)
- EX-10.41 Amended and Restated License Agreement (Filed With SEC on November 9, 2007)
- EX-10.42 STOCK PURCHASE AGREEMENT (Filed With SEC on November 6, 2007)
- FINANCIAL STATEMENTS (Filed With SEC on August 1, 2007)
- FINANCIAL STATEMENTS (Filed With SEC on August 1, 2007)
- FINANCIAL STATEMENTS (Filed With SEC on August 1, 2007)
- EX-10.28 COMPENSATION INFORMATION (Filed With SEC on May 7, 2007)
- Ex-10.15 Amended License & Supply Agreement (Filed With SEC on March 9, 2007)
- SUBSCRIPTION AGREEMENT (Filed With SEC on December 14, 2006)
- Ex-10.36 Partial Assignment of License & Supply Agreement (Filed With SEC on November 3, 2006)
- Ex-10.37 Collaboration and License Agreement (Filed With SEC on November 3, 2006)
- EX-10.1 COMPENSATION INFORMATION FOR EXECUTIVE OFFICERS (Filed With SEC on November 3, 2006)
- EX-10.2 2007 EXECUTIVE BONUS COMPENSATION PLAN (Filed With SEC on November 3, 2006)
- EX-10.33 AMENDMENT DATED MAY 23, 2006 (Filed With SEC on August 9, 2006)
- EX-10.34 AMENDMENT DATED JUNE 30, 2006 (Filed With SEC on August 9, 2006)
- EX-10.35 FORM OF STOCK OPTION AGREEMENT UNDER THE AMENDED AND RESTATED 2004 NON-EMPLOYEE DIRECTOR'S STOCK OPTION PLAN (Filed With SEC on August 9, 2006)
- EX-10.1 AMENDED AND RESTATED STOCK OPTION PLAN (Filed With SEC on April 27, 2006)
- EX-10.1 COMPENSATION INFORMATION (Filed With SEC on November 7, 2005)
- Exhibit No (Filed With SEC on October 12, 2005)
- EX-10.1 COMPENSATION INFORMATION (Filed With SEC on August 12, 2005)
- Ex-10.27 Sublease Agreement dated April 1, 2005, as amended (Filed With SEC on July 27, 2005)
- Ex-10.28 Employment Agreement dated January 1, 2005 (Filed With SEC on July 27, 2005)
- Ex-10.1 Purchase Agreement with Orion Corporation (Filed With SEC on March 7, 2005)
- Ex-10.2 Amended and Restated License Supply Agreement (Filed With SEC on March 7, 2005)
- Ex-10.24 Joint Collaboration & License Agreement (Filed With SEC on May 7, 2004)
- Prostarine for the treatment of a benign prostate enlargement that results in obstruction of the urinary tract (Filed With SEC on January 15, 2004)
- Prostarine for the treatment of a benign prostate enlargement that results in obstruction of the urinary tract (Filed With SEC on January 15, 2004)
- Prostarine for the treatment of a benign prostate enlargement that results in obstruction of the urinary tract (Filed With SEC on January 15, 2004)
- Prostarine for the treatment of a benign prostate enlargement that results in obstruction of the urinary tract (Filed With SEC on January 15, 2004)
- Prostarine for the treatment of a benign prostate enlargement that results in obstruction of the urinary tract (Filed With SEC on January 15, 2004)
- Prostarine for the treatment of a benign prostate enlargement that results in obstruction of the urinary tract (Filed With SEC on December 22, 2003)
- Prostarine for the treatment of a benign prostate enlargement that results in obstruction of the urinary tract (Filed With SEC on December 22, 2003)